IS5746A - Tetrahýdrókínólín afleiður sem glysín mótlyf - Google Patents

Tetrahýdrókínólín afleiður sem glysín mótlyf

Info

Publication number
IS5746A
IS5746A IS5746A IS5746A IS5746A IS 5746 A IS5746 A IS 5746A IS 5746 A IS5746 A IS 5746A IS 5746 A IS5746 A IS 5746A IS 5746 A IS5746 A IS 5746A
Authority
IS
Iceland
Prior art keywords
tetrahydroquinoline derivatives
glycine antagonists
antagonists
glycine
tetrahydroquinoline
Prior art date
Application number
IS5746A
Other languages
English (en)
Inventor
Di Fabio Romano
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of IS5746A publication Critical patent/IS5746A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS5746A 1998-06-10 2000-11-30 Tetrahýdrókínólín afleiður sem glysín mótlyf IS5746A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives
PCT/EP1999/003936 WO1999064411A1 (en) 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists

Publications (1)

Publication Number Publication Date
IS5746A true IS5746A (is) 2000-11-30

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5746A IS5746A (is) 1998-06-10 2000-11-30 Tetrahýdrókínólín afleiður sem glysín mótlyf

Country Status (34)

Country Link
US (3) US6362199B1 (is)
EP (1) EP1086093B1 (is)
JP (1) JP2002517492A (is)
KR (1) KR100586762B1 (is)
CN (1) CN1173970C (is)
AP (1) AP2000002008A0 (is)
AR (1) AR018632A1 (is)
AT (1) ATE301650T1 (is)
AU (1) AU753867B2 (is)
BG (1) BG105123A (is)
BR (1) BR9911145A (is)
CA (1) CA2334727C (is)
CO (1) CO5080785A1 (is)
CZ (1) CZ293605B6 (is)
DE (1) DE69926632T2 (is)
DK (1) DK1086093T3 (is)
EA (1) EA003276B1 (is)
EE (1) EE200000733A (is)
ES (1) ES2249010T3 (is)
HK (1) HK1034079A1 (is)
HR (1) HRP20000845A2 (is)
HU (1) HUP0102767A3 (is)
ID (1) ID27845A (is)
IL (2) IL140062A0 (is)
IS (1) IS5746A (is)
MY (1) MY125037A (is)
NO (1) NO321904B1 (is)
NZ (1) NZ508638A (is)
OA (1) OA11564A (is)
PE (1) PE20000724A1 (is)
PL (1) PL197160B1 (is)
TR (1) TR200003652T2 (is)
TW (1) TWI229079B (is)
WO (1) WO1999064411A1 (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7211672B2 (en) * 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
WO2006091674A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
CA2232509A1 (en) 1995-09-29 1997-04-10 Glaxo Wellcome Spa Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
TR200003652T2 (tr) 2001-04-20
KR20010052722A (ko) 2001-06-25
US20020169186A1 (en) 2002-11-14
DK1086093T3 (da) 2005-11-28
NO20006227L (no) 2001-02-08
TWI229079B (en) 2005-03-11
IL140062A0 (en) 2002-02-10
ES2249010T3 (es) 2006-03-16
EP1086093A1 (en) 2001-03-28
ATE301650T1 (de) 2005-08-15
EA003276B1 (ru) 2003-04-24
EE200000733A (et) 2002-06-17
NZ508638A (en) 2003-08-29
OA11564A (en) 2004-05-24
BR9911145A (pt) 2001-03-06
AU4509299A (en) 1999-12-30
NO321904B1 (no) 2006-07-17
HRP20000845A2 (en) 2001-10-31
EP1086093B1 (en) 2005-08-10
AR018632A1 (es) 2001-11-28
PL344694A1 (en) 2001-11-19
IL140062A (en) 2007-05-15
CZ20004587A3 (en) 2001-05-16
ID27845A (id) 2001-04-26
US6413985B1 (en) 2002-07-02
JP2002517492A (ja) 2002-06-18
EA200001165A1 (ru) 2001-06-25
NO20006227D0 (no) 2000-12-07
KR100586762B1 (ko) 2006-06-08
US20020052391A1 (en) 2002-05-02
DE69926632D1 (de) 2005-09-15
US6495566B2 (en) 2002-12-17
CN1173970C (zh) 2004-11-03
US6362199B1 (en) 2002-03-26
CA2334727A1 (en) 1999-12-16
DE69926632T2 (de) 2006-01-19
PE20000724A1 (es) 2000-08-17
HUP0102767A3 (en) 2003-01-28
AU753867B2 (en) 2002-10-31
HUP0102767A2 (hu) 2001-12-28
CO5080785A1 (es) 2001-09-25
HK1034079A1 (en) 2001-10-12
PL197160B1 (pl) 2008-03-31
CZ293605B6 (cs) 2004-06-16
CN1311785A (zh) 2001-09-05
BG105123A (en) 2001-11-30
CA2334727C (en) 2009-08-04
AP2000002008A0 (en) 2000-12-31
WO1999064411A1 (en) 1999-12-16
MY125037A (en) 2006-07-31

Similar Documents

Publication Publication Date Title
NO20013003D0 (no) Kinolin-derivater
DK1073639T3 (da) Chinolinderivater
ATE250036T1 (de) Chinolinderivate
ATE240327T1 (de) 1,2-annelierte chinolinderivate
IS5859A (is) 4-karbóxýamínó-2-setinn-1 ,2, 3, 4-tetrahýdrókínólín sem CETP latar
ATE229005T1 (de) Chinolinderivate
IS4953A (is) Tetrahýdrókínólín afleiður sem EAA mótlyf
IS4677A (is) Tetrahýdrókínólín sem NMDA mótlyf
IS5746A (is) Tetrahýdrókínólín afleiður sem glysín mótlyf
ID26665A (id) Antagonis vla-4
FI980222A0 (fi) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
IS5897A (is) Úreídópíperidín afleiður sem valvís NK3 viðtakamótlyf fyrir manneskjur
SI1086093T1 (sl) Derivati tetrahidrokinolina kot antagonisti glicina
NO20013095L (no) Arrangement for sömforberedelse
FI980433A0 (fi) Foerfarande foer utnyttjande i samband med tillslutandet av en vaetskefoerpackning
UA2392S (uk) Нитка андезіто-базальтова